keyword
MENU ▼
Read by QxMD icon Read
search

cancer and venous thromboembolism

keyword
https://www.readbyqxmd.com/read/28334639/inferior-vena-cava-filters-in-patients-with-cancer-and-venous-thromboembolism-vte-does-not-improve-clinical-outcomes-a-population-based-study
#1
Ann Brunson, Gwendolyn Ho, Richard White, Ted Wun
BACKGROUND: There are few studies that have determined clinical outcomes following inferior vena cava filter (IVCF) insertion in cancer patients hospitalized for acute deep-vein-thrombosis (DVT) or pulmonary embolism (PE). METHODS AND RESULTS: We analyzed hospital discharge records of all patients with active cancer who were admitted to a California hospital specifically for acute DVT or PE between 2005 through 2009. Propensity and competing risk methodology were used to determine if IVCF-use lowered either 30-day mortality or the risk of recurrent PE, DVT, and major bleeding within 180days...
March 16, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28332985/prostate-cancer-radiation-therapy-and-risk-of-thromboembolic-events
#2
Cecilia Bosco, Hans Garmo, Jan Adolfsson, Pär Stattin, Lars Holmberg, Per Nilsson, Adalsteinn Gunnlaugsson, Anders Widmark, Mieke Van Hemelrijck
PURPOSE: To investigate the risk of thromboembolic disease (TED) after radiation therapy (RT) with curative intent for prostate cancer (PCa). PATIENTS AND METHODS: We identified all men who received RT as curative treatment (n=9410) and grouped according to external beam RT (EBRT) or brachytherapy (BT). By comparing with an age- and county-matched comparison cohort of PCa-free men (n=46,826), we investigated risk of TED after RT using Cox proportional hazard regression models...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28321922/retrospective-evaluation-of-venous-thromboembolism-vte-are-all-transient-provoking-events-the-same
#3
Chong Chyn Chua, Hui Yin Lim, Mark Tacey, Harshal Nandurkar, Prahlad Ho
OBJECTIVES: Venous thromboembolism (VTE) provoked by transient risk factors has traditionally been classified as a single entity with lower risk of recurrence. We evaluated the association between different categories of transient provoking factors and the relative risk of recurrence. METHODS: Retrospective evaluation of VTE events in non-cancer patients from July 2011 to December 2012 at two tertiary institutions in Australia with a minimum follow up of 24 months...
March 21, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28317330/long-term-risk-of-venous-thromboembolism-recurrence-after-isolated-superficial-vein-thrombosis
#4
Jean-Philippe Galanaud, Marie-Antoinette Sevestre, Gilles Pernod, Susan R Kahn, Céline Genty, Hugo Terrisse, Dominique Brisot, Jean-Luc Gillet, Isabelle Quéré, Jean-Luc Bosson
BACKGROUND: Isolated superficial vein thrombosis (iSVT) (without concomitant deep vein thrombosis (DVT) or pulmonary embolism (PE)) is a frequent event but available data on long-term outcomes are scarce and retrospective. Therefore, we aimed to determine prospectively the risk and type of venous thromboembolic (VTE) recurrence after iSVT and compare it with that of proximal DVT. METHODS: Using data from the prospective, multicentre, observational, OPTIMEV study, we assessed at three years and after anticoagulants were stopped, the incidence and the type of VTE recurrence (iSVT/DVT/PE) of patients with a first objectively confirmed iSVT without cancer (n=285) and compared this to patients with a first proximal DVT without cancer (n=262)...
March 20, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28315167/development-of-a-predictive-model-for-6-month-survival-in-patients-with-venous-thromboembolism-and-solid-malignancy-requiring-ivc-filter-placement
#5
Steven Y Huang, Bruno C Odisio, Sharjeel H Sabir, Joe E Ensor, Andrew S Niekamp, Tam T Huynh, Michael Kroll, Sanjay Gupta
PURPOSE: Our purpose was to develop a predictive model for short-term survival (i.e. <6 months) following inferior vena cava filter placement in patients with venous thromboembolism (VTE) and solid malignancy. METHODS: Clinical and laboratory parameters were retrospectively reviewed for patients with solid malignancy who received a filter between January 2009 and December 2011 at a tertiary care cancer center. Multivariate Cox proportional hazards modeling was used to assess variables associated with 6 month survival following filter placement in patients with VTE and solid malignancy...
March 17, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28301216/bioidentical-menopausal-hormone-therapy-registered-hormones-non-oral-estradiol%C3%A2-%C3%A2-%C3%A2-progesterone-are-optimal
#6
M L'Hermite
The many advantages of registered bioidentical sex hormones over registered, conventional, non-bioidentical menopausal hormone therapy (MHT) are considered. The transdermal route of estrogen administration avoids excess venous thromboembolic and ischemic stroke events. There is some indication that conjugated equine estrogens are more thrombogenic and most likely induce some hypertensive responses; estradiol might also be superior to conjugated equine estrogens (CEE) in terms of global cardiovascular health...
March 16, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28290648/deep-venous-thrombosis-and-pulmonary-embolism-current-therapy
#7
Jason Wilbur, Brian Shian
Pulmonary embolism and deep venous thrombosis are the two most important manifestations of venous thromboembolism (VTE), which is the third most common life-threatening cardiovascular disease in the United States. Anticoagulation is the mainstay of VTE treatment. Most patients with deep venous thrombosis or low-risk pulmonary embolism can be treated in the outpatient setting with low-molecular-weight heparin and a vitamin K antagonist (warfarin) or direct-acting oral anticoagulants. Inpatient treatment of VTE begins with parenteral agents, preferably low-molecular-weight heparin...
March 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28288527/tinzaparin-for-long-term-treatment-of-venous-thromboembolism-in-patients-with-cancer
#8
M José Martínez-Zapata, Alexander G Mathioudakis, Shaker A Mousa, Rupert Bauersachs
Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding. Thus, long-term treatment with anticoagulants for secondary prevention is challenging. The objective of this review was to evaluate current evidence on the safety and efficacy of tinzaparin compared with other anticoagulants for long-term VTE treatment in patients with cancer. Based on a preregistered protocol, we identified randomized controlled trials (RCTs) comparing long-term tinzaparin (therapeutic dose: 175 IU/kg) versus other anticoagulants for at least 3 months after an acute episode of VTE that included adult patients with underlying malignancy...
January 1, 2017: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28288526/performance-of-khorana-risk-score-for-prediction-of-venous-thromboembolism-in-patients-with-hepatocellular-carcinoma
#9
Y Wang, B M Attar, H E Fuentes, J Yu, Huiyuan Zhang, A J Tafur
Cancer-associated venous thromboembolism (VTE) is one of the leading causes of mortality and morbidity among patients with malignancy. The Khorana risk score (KRS) is currently the best validated risk assessment model to stratify risks of VTE development in ambulatory patients with cancer. In the current study, we assessed the performance of KRS in patients with hepatocellular carcinoma (HCC). We retrospectively analyzed patients with diagnosis of HCC (screened by International Classification of Diseases [ ICD-9] and ICD-10 code, confirmed with radiographic examination and/or histopathology) at a large public hospital over 15 years (January 2000 through July 2015)...
January 1, 2017: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/28284738/procedure-specific-risks-of-thrombosis-and-bleeding-in-urological-non-cancer-surgery-systematic-review-and-meta-analysis
#10
REVIEW
Kari A O Tikkinen, Samantha Craigie, Arnav Agarwal, Reed A C Siemieniuk, Rufus Cartwright, Philippe D Violette, Giacomo Novara, Richard Naspro, Chika Agbassi, Bassel Ali, Maha Imam, Nofisat Ismaila, Denise Kam, Michael K Gould, Per Morten Sandset, Gordon H Guyatt
CONTEXT: Pharmacological thromboprophylaxis involves a trade-off between a reduction in venous thromboembolism (VTE) and increased bleeding. No guidance specific for procedure and patient factors exists in urology. OBJECTIVE: To inform estimates of absolute risk of symptomatic VTE and bleeding requiring reoperation in urological non-cancer surgery. EVIDENCE ACQUISITION: We searched for contemporary observational studies and estimated the risk of symptomatic VTE or bleeding requiring reoperation in the 4 wk after urological surgery...
March 8, 2017: European Urology
https://www.readbyqxmd.com/read/28279597/inferior-vena-cava-filters-in-pulmonary-embolism-a-historic-controversy
#11
Carlos Jerjes-Sanchez, David Rodriguez, Aline Navarrete, Carolina Parra-Cantu, Jorge Joya-Harrison, Eduardo Vazquez, Alicia Ramirez-Rivera
OBJECTIVE: Rationale for non-routine use of inferior venous cava filters (IVCF) in pulmonary embolism (PE) patients. METHODS: Thrombosis mechanisms involved with IVCF placement and removal, the blood-contacting medical device inducing clotting, and the inorganic polyphosphate in the contact activation pathway were analyzed. In addition, we analyzed clinical evidence from randomized trials, including patients with and without cancer. Furthermore, we estimated the absolute risk reduction (ARR), the relative risk reduction (RRR), and the number needed to treat (NNT) based on the results of each study using a frequency table...
March 6, 2017: Archivos de Cardiología de México
https://www.readbyqxmd.com/read/28273666/prophylaxis-and-treatment-of-cancer-associated-venous-thromboembolism-comparison-hematologist-oncologists-versus-angiologist-phlebologists
#12
Axel Matzdorff, Bettina Ledig, Markus Stücker, Hanno Riess
No abstract text is available yet for this article.
2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28267367/systematic-indirect-comparison-of-ospemifene-versus-local-estrogens-for-vulvar-and-vaginal-atrophy
#13
N Bruyniks, N Biglia, S Palacios, A O Mueck
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio(®)) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA). A literature search was carried out of clinical efficacy/safety trials of local vaginal estrogens in VVA approved in Europe. For efficacy comparison, studies had to be placebo-controlled and of 12 weeks' duration. For safety comparison, studies had to be ≥40 weeks' duration. Efficacy endpoints were the difference between active and placebo in change from baseline to week 12 for symptoms, vaginal pH, and maturation value (MV)...
March 7, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28266773/long-term-outcomes-of-cancer-related-isolated-distal-deep-vein-thrombosis-the-optimev-study
#14
Jean-Philippe Galanaud, Marie-Antoinette Sevestre, Gilles Pernod, Céline Genty, Sébastien Richelet, Susan R Kahn, Carine Boulon, Hugo Terrisse, Isabelle Quéré, Jean-Luc Bosson
BACKGROUND: Isolated distal deep vein thrombosis (iDDVT) (infra-popliteal DVT without pulmonary embolism [PE]) is a frequent event and, in the absence of cancer, is usually considered to be a minor form of venous thromboembolism (VTE). However, the clinical significance of cancer-related iDDVT is unknown. METHODS: Using data from the observational, prospective multicentre OPTIMEV cohort, we compared, at 3 years, the incidences of death, VTE recurrence and major bleeding in patients with cancer-related iDDVT with cancer patients with isolated proximal DVT (matched 1:1 on age and sex) and with patients with iDDVT without cancer (matched 1:2 on age and sex)...
March 7, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28265124/initiating-and-managing-patients-with-venous-thromboembolism-on-anticoagulant-drugs-a-practical-overview
#15
REVIEW
Raj S Kasthuri, Stephan Moll
Several new oral anticoagulants have recently been approved for the treatment of venous thromboembolism (VTE). In this review, we discuss the currently approved drugs and the factors that influence the choice of anticoagulant in a given patient. Once anticoagulation is initiated, periodic monitoring of adequacy of anticoagulation may be necessary depending on the choice of anticoagulant and patient-related factors, such as renal function. Situations that may warrant need for monitoring and the tests available for this purpose are discussed...
March 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/28264198/risk-assessment-scores-for-cancer-associated-venous-thromboembolic-disease
#16
Dana Angelini, Alok A Khorana
Current guidelines recommend that patients with cancer be assessed for venous thromboembolism (VTE) risk at the time of chemotherapy initiation and periodically thereafter. Rates of VTE vary substantially among cancer patients. Multiple clinical factors contribute to VTE risk, including the primary site of cancer, extent of disease, interventions including major surgery, hospitalization, and systemic therapy. However, risk of VTE cannot reliably be predicted based on a single risk factor or biomarker. Within the last decade, risk assessment scores have been developed in cancer patients to more reliably predict thromboembolic events...
March 6, 2017: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/28262237/outcome-after-discontinuing-anticoagulant-therapy-in-women-with-venous-thromboembolism-during-hormonal-use
#17
Ángeles Blanco-Molina, Javier Trujillo-Santos, Raffaele Pesavento, Vladimir Rosa, Conxita Falgá, Carles Tolosa, Lucia Mazzolai, Ángel Sampériz, Rita Duce, Manuel Monreal
INTRODUCTION: Whether women developing venous thromboembolism (VTE) while using hormonal therapy should be classified as having "unprovoked" or "provoked" VTE is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic VTE recurrences after discontinuing anticoagulation in 3 subgroups of women aged ≤50years without cancer, pregnancy or puerperium: (1) those with hormonal therapy and no additional risk factors (hormonal users only); (2) those with unprovoked VTE; and (3) those with additional risk factors, with or without hormonal therapy...
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28262229/women-thrombosis-and-cancer-a-gender-specific-analysis
#18
Dominique Farge, Henri Bounameaux, Rupert M Bauersachs, Benjamin Brenner
Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis. HIGHLIGHTS: HASH(0x4a8c448)
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28262228/gender-differences-in-patients-with-venous-thromboembolism-and-five-common-sites-of-cancer
#19
Francisco Martín-Martos, Javier Trujillo-Santos, Jorge Del Toro, Alessandra Bura-Riviere, Alicia Lorenzo, Giovanni Barillari, Silvia Soler, Isabelle Mahè, Joan Carles Sahuquillo, Manuel Monreal
BACKGROUND: The outcome of cancer patients with venous thromboembolism (VTE) may differ according to gender. METHODS: We used the RIETE database to compare the rate of VTE recurrences, major bleeding and mortality in patients with lung, colorectal, pancreatic, hematologic or gastric cancer during the course of anticoagulation, according to gender. RESULTS: As of January 2016, 11,055 patients with active cancer were enrolled: 1,727 had lung cancer, 1,592 colorectal, 840 hematologic, 517 pancreatic and 459 had gastric cancer...
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28262225/uterine-bleeding-during-anticoagulation-in-women-with-venous-thromboembolism
#20
Farès Moustafa, Sonia Fernández, Carmen Fernández-Capitán, José Antonio Nieto, José María Pedrajas, Adriana Visoná, Beatriz Valero, Pablo Javier Marchena, Andrei Braester, Manuel Monreal
BACKGROUND: Women presenting with uterine bleeding during the course of anticoagulant therapy for venous thromboembolism (VTE) present a difficult therapeutic dilemma due to the absence of evidence-based recommendations. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to assess the clinical characteristics of women presenting with uterine bleeding during anticoagulation for VTE, its frequency, time course, management and 30-day outcomes...
March 2017: Thrombosis Research
keyword
keyword
39888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"